Schizophrenia Research
Volume 43, Issue 2 , Pages 135-145 , 16 June 2000

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life

  • L Voruganti

      Affiliations

    • Department of Psychiatry, University of Western Ontario, London, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Present address: London Psychiatric Hospital, 850 Highbury Avenue, London, ON, Canada N6A 4H1. Tel.: +1-519-455-5110; fax: +1-519-858-4607
    • ,
  • L Cortese

      Affiliations

    • Department of Psychiatry, University of Western Ontario, London, Ontario, Canada
    • ,
  • L Oyewumi

      Affiliations

    • Department of Psychiatry, University of Western Ontario, London, Ontario, Canada
    • ,
  • Z Cernovsky

      Affiliations

    • Department of Psychiatry, University of Western Ontario, London, Ontario, Canada
    • ,
  • S Zirul

      Affiliations

    • Department of Psychiatry, University of Western Ontario, London, Ontario, Canada
    • ,
  • A Awad

      Affiliations

    • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

Received 12 May 1999 ,Accepted 11 July 1999.

References 

  1. American Psychiatric Association . DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: APA; 1994;
  2. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18:63–101
  3. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr. Bull. 1993;19:609–618
  4. Awad A, Hogan T, Voruganti L, Heslegrave R. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol. 1995;10(Suppl. 3):123–132
  5. Awad AG, Voruganti L, Heslegrave R. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual. Life Res. 1997;6:21–26
  6. Awad AG, Rylander A, Angus C, Lapierre YD. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. J. Psychiatry Neurosci. 1997;22(4):244–248
  7. Barnes TRE. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154:672–676
  8. Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: Development and final revision of a health status measure. Med. Care. 1981;19(8):787–805
  9. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv. Rev. Psychiatry. 1997;4(5):255–271
  10. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourett's disorder. Am. J. Psychiatry. 1988;145:621–624
  11. Caine ED, Polinsky RJ. Haloperidol-induced dysphoria in patients with Tourette syndrome. Am. J. Psychiatry. 1979;136:1216–1217
  12. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side effects. Br. J. Psychiatry. 1995;166:650–653
  13. Emerich D, Sanberg P. Neuroleptic dysphoria. Biol. Psychiatry. 1991;29:201–203
  14. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 1976;33:766–771
  15. Fibiger HC, Phillips AG, Blaha CD. Dopamine and the neural substrates of reward: implications for the mechanisms of action of antidepressant drugs. In: Dopamine and Mental Depression.  Gessa GL,  Serra G editor. Advances in the Biosciences. Vol. 77:New York: Pergamon Press; 1990;p. 51–62
  16. Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br. J. Psychiatry. 1997;170:422–425
  17. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am. J. Psychiatry. 1997;154(6):799–804
  18. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare; 1976;revised 1976
  19. Hale T. Will the new antipsychotics improve the treatment of schizophrenia?. Br. Med. J. 1993;307:749–750
  20. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology. 1998;18(1):41–49
  21. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J. Clin. Psychiatry. 1996;57(9):66–76
  22. Heinrichs D, Hanlon E, Carpenter W. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1996;10:388–398
  23. Hogan TP, Awad AG, Eastwood R. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminant validity. Psychol. Med. 1983;13:177–183
  24. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol. Med. 1992;22:347–352
  25. Hollister LE. Complications from the use of tranquilising drugs. New Engl. J. Med. 1957;257:170–177
  26. Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987;13:261
  27. Lewander T. Neuroleptics and neuroleptic-induced deficit syndrome. Acta Psychiatr. Scand. 1994;89(380):8–13
  28. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. New York: Oxford University Press; 1996;
  29. Meltzer HY, Cola P, Way L, Thompson P, Bastani B, Davies M, et al. Cost-effectiveness of clozapine in neuroleptic resistant schizophrenia. Am. J. Psychiatry. 1993;150:1630–1638
  30. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman J. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. Schizophr. Res. 1997;24(1–2):265
  31. Owens DGC. Adverse effects of antipsychotic agents. do newer agents offer advantages?. Drugs. 1996;51(6):895–930
  32. Perkins DO, Lieberman JA. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. Am. J. Psychiatry. 1998;155:272–276
  33. Reid WH. The treatment of psychosis: resetting the drug cost ‘thermostat’. J. clinical psychiatry. 1994;55(9 Suppl. B):166–168
  34. Revicki D, Luce BR. Pharmacoeconomics research applied to psychopharmacology development and evaluation: Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol. Bull. 1995;31:57–65
  35. Robert G, Kennedy P. Establishing cost-effectiveness of atypical neuroleptics. Br. J. Psychiatry. 1997;171:145–147
  36. Rotrosen J, Adler L. The importance of side effects in the development of new antipsychotic drugs. Psychiatr. Ann. 1995;25(5):306–310
  37. Russell K, Hagenmeyer-Houser SH, Sanberg PR. Haloperidol-induced emotional defecation: possible model for neuroleptic anxiety syndrome. Psychopharmacology. 1987;91:45–49
  38. Simpson G, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970;212(Suppl.):11–19
  39. Singh MM, Smith JM. Kinetics and dynamics of response to haloperidol in acute schizophrenia: a longitudinal study of the therapeutic process. Compr. Psychiatry. 1973;14:393–414
  40. Singh MM, Kay SR. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biol. Psychiatry. 1979;14:277–294
  41. Thomas CS, Lewis S. Which atypical antipsychotic?. Br. J. Psychiatry. 1998;172:159–163
  42. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry. 1998;55:250–258
  43. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr. Bull. 1996;22(3):475–483
  44. vanPutten T, May PRA. Akinetic depression in schizophrenia. Arch. Gen. Psychiatry. 1978;35:1101–1105
  45. vanPutten T, May PRA, Marder SR, Wittmann L. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry. 1981;38:187–190
  46. Voruganti L, Awad AG. Sickness Impact Profile (SIP) as a Measure of Patients' Quality of Life (QOL) in Clinical Trials Involving Antipsychotic Drugs. Annual Meeting of the American College of Neuro-psychopharmacology (ACNP), Puerto Rico, December 1995 (abstract). 1995;
  47. Voruganti L, Awad AG, Heslegrave R. Neuroleptic dysphoria may be the missing link between substance abuse and schizophrenia. J. Nerv. Ment. Dis. 1997;185:463–465
  48. Voruganti L, Heslegrave R, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J. Psychiatry Neurosci. 1997;22:267–274
  49. Weiden P, Mann JJ, Dixon L, Haas G, DeChillo N, Frances AJ. Is neuroleptic dysphoria a healthy response?. Compr. Psychiatry. 1989;30:543–552
  50. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry. 1996;57(11):53–60
  51. Wise R. The neurobiology of craving: implications for the understanding and treatment of addiction. J. Abnorm. Psychol. 1988;97:118–132

PII: S0920-9964(99)00154-1

Schizophrenia Research
Volume 43, Issue 2 , Pages 135-145 , 16 June 2000

Article Tools